| Literature DB >> 28694465 |
Wei Zhang1, Guan Wang1, Ying Wang1, Yong Jin1, Lihua Zhao1, Qiang Xiong1, Lining Zhang1, Lisha Mou2, Rongfeng Li1, Haiyuan Yang3, Yifan Dai4.
Abstract
Complement protein C3 is the pivotal component of the complement system. Previous studies have demonstrated that C3 has implications in various human diseases and exerts profound functions under certain conditions. However, the delineation of pathological and physiological roles of C3 has been hampered by the insufficiency of suitable animal models. In the present study, we applied the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) system to target the C3 gene in porcine fetal fibroblasts. Our results indicated that CRISPR/Cas9 targeting efficiency was as high as 84.7%, and the biallelic mutation efficiency reached at 45.7%. The biallelic modified colonies were used as donor for somatic cell nuclear transfer (SCNT) technology to generate C3 targeted piglets. A total of 19 C3 knockout (KO) piglets were produced and their plasma C3 protein was undetectable by western blot analysis and ELISA. The hemolytic complement activity and complement-dependent cytotoxicity assay further confirmed that C3 was disrupted in these piglets. These C3 KO pigs could be utilized as a valuable large animal model for the elucidation of the roles of C3.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28694465 PMCID: PMC5503937 DOI: 10.1038/s41598-017-05400-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1CRISPR/Cas9-mediated C3 gene targeting in PFFs. (a) Schematic diagram of sgRNA targeting the exon 26 of the C3 gene. sgRNA targeting sites are highlighted in red. PAM sequences are underlined and highlighted in blue. (b) T7E1 assay for CRISPR/Cas9-mediated cleavage at target site in PFFs. WT1 and WT2: PCR products of untransfected PFFs treated with T7E1; sgRNA1 and sgRNA2: PCR products of PFFs transfected with Cas9-sgRNA1 and Cas9-sgRNA2 treated with T7E1. (c) Biallelic mutation donor cell sequences for SCNT. The wild-type sequence is shown at the top of the target sequence. The sgRNA sequences are highlighted in red, PAM sequences in blue, and insertions in green; deletion (−); insertion (+).
C3 targeting in PFFs using the CRISPR/Cas9 system.
| Monoallelic-KO | Biallelic-KO | Indel-positive |
|---|---|---|
| 18/46 (39.1%) | 21/46 (45.7%) | 39/46 (84.7%) |
Somatic cell nuclear transfer results for the generation of C3 knockout cloned pigs.
| Cell pool | Number of transferred embryos | Number of recipients | Number of pregnancies | Number of piglets born | Number of mutants |
|---|---|---|---|---|---|
| C-1, C-12, C-20 | 348 | 1 | 0 | — | — |
| C-1, C-12, C-20 | 335 | 1 | 0 | — | — |
| C-1, C-12, C-20 | 356 | 1 | 1 | 6 | 6 |
| C-1, C-12, C-20 | 375 | 1 | 0 | — | — |
| C-1, C-12, C-20 | 375 | 1 | 0 | — | — |
| C-1, C-12, C-20 | 386 | 1 | 0 | — | — |
| C-1, C-4, C-12, C-20 | 320 | 1 | 0 | — | — |
| C-1, C-4, C-12, C-20 | 323 | 1 | 1 | 10 | 10 |
| C-1, C-4, C-12, C-20 | 325 | 1 | 1 | 3 | 3 |
| Total | 3143 | 9 | 3 (33%) | 19 | 19 |
Figure 2Generation of C3 mutant piglets via SCNT. (a) Photograph of newborn cloned piglets carrying C3 gene mutation. (b) C3 genotypes of cloned piglets. The wild-type (WT) sequence is shown at the top in which the sgRNA sequences are highlighted in red, PAM sequences in blue, and insertions in green. WT: wild type; deletion (−); insertion (+).
Details on the generated C3 KO piglets.
| Piglets | Genotypes | Indel | Birth weight (kg) | Donor cell |
|---|---|---|---|---|
|
| wt | |||
| 1# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.5 | C-1 |
| GGCCGTCAAATGGCTGA--CTGGAG | ||||
| 2# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.85 | C-1 |
| GGCCGTCAAATGGCTGA--CTGGAG | ||||
| 3# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.80 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG | ||||
| 4# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 1.20 | C-1 |
| GGCCGTCAAATGGCTGA--CTGGAG | ||||
| 5# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.95 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG | ||||
| 6# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 1.05 | C-1 |
| GGCCGTCAAATGGCTGA--CTGGAG | ||||
| 7# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.94 | C-1 |
| GGCCGTCAAATGGCTGA--CTGGAG | ||||
| 8# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 1.08 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG | ||||
| 9# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.705 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG | ||||
| 10# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.804 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG | ||||
| 11# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.979 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG | ||||
| 12# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.938 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG | ||||
| 13# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 1.067 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG | ||||
| 14# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.970 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG | ||||
| 15# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.605 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG | ||||
| 16# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.450 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG | ||||
| 17# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.360 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG | ||||
| 18# | GGCCGTCAAA | +1, −198 | 0.577 | C-12 |
| 19# | GGCCGTCAAATGG----TCCTGGAG | −4/−2 | 0.724 | C-1 |
| GGCCGTCAAATGGCTG--CCTGGAG |
sgRNA sequences are highlighted in red, PAM sequences in blue, and insertions in green. WT: wild type; deletion (−); insertion: (+).
Figure 3C3 protein expression analysis of piglet serum. (a) Stain-free gel image of total loaded serum proteins. (b) Western blot of serum C3 protein of cloned piglets compared to that of wild type piglets. Full-length blot is presented in Supplementary Figure S3. (c) Serum C3 protein levels of C3 KO piglets and wild type controls were assessed by ELISA (**P < 0.01, data are shown as mean ± SEM, n = 3).
Figure 4Immunohistochemistry (left) and western blot (right) analysis of C3 protein in various tissues. C3 protein was not detectable in liver, lung, kidney, and spleen of C3 KO piglets. Full-length blots are presented in Supplementary Figures S4–S7. The scale bar is 100 μm.
Figure 5Hemolytic complement activity of pig serum and effects on anti-human cells. (a) Total hemolytic complement activities were determined by Dian Diagnostics. (b) The percentages of 293T cell lysis mediated by various concentrations of WT pig serum, heat-inactivated WT serum, C3 KO piglet serum, and human serum. Lysis of 293T cells was significantly reduced when incubated in serum of C3 KO piglets compared to WT controls. (**P < 0.01, data are shown as mean ± SEM, n = 5). ND: Not detectable.